Agendia, Inc.
Agendia is a leading molecular diagnostics company that develops and markets FFPE-based genomic diagnostic products, which help support physicians with their complex treatment decisions. AgendiaÕs tests were developed using an unbiased gene selection by analyzing the complete human genome. This includes MammaPrint as well as BluePrint, a molecular subtyping assay that provides deeper insight leading to more clinically actionable biology. MammaPrint is the only breast cancer recurrence assay backed by peer-reviewed, prospective outcome data. These tests can help physicians assess a patientÕs individual risk for metastasis, which patients may benefit from chemo, hormonal, or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods. In addition, Agendia has a pipeline of other genomic products in development. The company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and the MINDACT trials. For more information, visit www.agendia.com. Twitter: http://www.twitter.com/Agendia Facebook: http://www.facebook.com/AgendiaInc YouTube: http://www.youtube.com/AgendiaInc
Biotechnology
50 - 200
Amsterdam, Netherlands
About

Agendia is a leading molecular diagnostics company that develops and markets FFPE-based genomic diagnostic products, which help support physicians with their complex treatment decisions. AgendiaÕs tests were developed using an unbiased gene selection by analyzing the complete human genome. This includes MammaPrint as well as BluePrint, a molecular subtyping assay that provides deeper insight leading to more clinically actionable biology. MammaPrint is the only breast cancer recurrence assay backed by peer-reviewed, prospective outcome data. These tests can help physicians assess a patientÕs individual risk for metastasis, which patients may benefit from chemo, hormonal, or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods.

In addition, Agendia has a pipeline of other genomic products in development. The company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and the MINDACT trials. For more information, visit www.agendia.com.

Twitter: http://www.twitter.com/Agendia
Facebook: http://www.facebook.com/AgendiaInc
YouTube: http://www.youtube.com/AgendiaInc

Site Traffic
  • 4168487 Global Rank
  • 1251219
    Netherlands
Traffic Sources
  • Search
    92.09%
  • Direct
    7.91%
  • Display
    0.00%
  • Mail
    0.00%
  • Referrals
    0.00%
  • Social
    0.00%
Powered by
Alexa Traffic Data
Global Rank 588,240
235,826
United States Rank 153,317
4,600
United States Page Views 22.0%
19.6%
Top Countries
Top Search Keywords
  • Breast
  • Testing
Ad Intelligence
  • Native
    0%
  • Standard
    0%
Ads Seen Recently
0
Longest Running Ad
Agendia, Inc.
Device
Mobile
Dimensions
other
Agendia, Inc. receives up to 0.2M pageviews per day, in countries such as United States.

They are headquartered at Amsterdam, Netherlands, and have 1 advertising & marketing contacts listed on Kochava. Agendia, Inc. works with Advertising technology companies such as DoubleClick.Net, Bizo, Twitter Ads, LinkedIn Ads, Google Floodlight Counter, AppNexus, Google Remarketing, AppNexus Segment Pixel, Facebook Custom Audiences, StackAdapt, StackAdapt Retageting.